Home › Myalgic Encephalomyelitis/Chronic Fatigue Syndrome › NCT07009691
Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS
Heart Rate Variability as an Autonomic Marker of Improvement in ME/CFS in a Hydrogen Water Treatment Study
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: Meets Institute of Medicine criteria for myalgic encephalomyelitis/chronic fatigue syndrome - Exclusion Criteria: Medical illness that explains presenting fatigue; Any psychosis. \-
About the study
The goal of this clinical trial is to learn if the OTC supplement, hydrogen water, works to treat the fatigue-related symptoms and functional limitations in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). It will also examine if heart rate variability (HRV) can be used to predict who will benefit from the hydrogen water treatment. The main questions it aims to answer are:
Does the OTC supplement, hydrogen water, work to reduce the fatigue-related symptoms and improve functioning in participants who have ME/CFS?
Can HRV be used to predict who will benefit from treatment with hydrogen water?
What is being tested
- Hydrogen water which is prepared from an OTC supplement. (dietary supplement)
Sponsor: Stony Brook University · Participants: 50 · Started: Jun 9, 2025
Contact the study team
- Fred Friedberg, PhD · Phone: 15167024213
Official record on ClinicalTrials.gov — NCT07009691
Locations in the U.S.
| New York | Stony Brook University, Stony Brook |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.